Physician profile
Christopher B Smith
NPI 1417997487
$1,140.50
in general payments reported to CMS, 2019-2025
22 companies · $64.95 in 2025
The $64.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.43 · 2020: $45.53 · 2021: $69.02 · 2022: $279 · 2023: $324 · 2024: $343 · 2025: $64.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $138.13 | 2022-2024 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.07 | 2022-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $120.27 | 2023-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $116.54 | 2020-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $91.40 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $88.08 | 2023-2024 | |
| Pfizer INC. | $54.39 | 2021-2024 | |
| Hologic Sales and Service, LLC | $51.73 | 2022-2024 | Thinprep 2000 Processor |
| Exact Sciences Corporation | $34.67 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $34.37 | 2020-2022 | |
| Boston Scientific Corporation | $34.19 | 2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $33.96 | 2019-2021 | |
| Abbott Laboratories | $33.21 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.07 | 2022 | |
| Astellas Pharma US INC | $29.60 | 2024 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.98 | 2022 | |
| Sanofi Pasteur INC. | $19.34 | 2022 | |
| Gilead Sciences, INC. | $17.81 | 2024 | |
| Daiichi Sankyo INC. | $16.99 | 2024 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $16.84 | 2022 | |
| Abbvie INC. | $16.38 | 2021 | |
| Coopersurgical, INC. | $14.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.